Market Research Blog – Page 11189 – New Product Development

Bronchopulmonary Dysplasia Treatment Market is expected to accumulate US$ 661.7 Million by registering a CAGR of 6.1% from 2022-2032

[308 Pages Report] The global bronchopulmonary dysplasia treatment market is expected to be worth US$ 346 million in 2022 and US$ 661.7 million by 2032, growing at a CAGR of 6.1% during the forecast period. The increasing cases of bronchopulmonary dysplasia, as well as the rise in premature births, can be attributed to the growth of the bronchopulmonary dysplasia treatment market. In the historical period 2016-2021, the market for bronchopulmonary dysplasia treatment grew at a CAGR of 5.9%.

Bronchopulmonary Dysplasia Treatment Market: Overview

Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia. On the other hand, research are developing stem cell therapy for novel therapeutic modality for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in the preterm infants.

Bronchopulmonary Dysplasia Treatment Market: Drivers and Restraints

According to the Airway estimates, in Europe and the U.S. up to 160,000 infants are at highest risk for the development of BPD collectively, each year. Similarly, With 73.6 million live births in Asia and a preterm rate <32 weeks of approximately 2.2%. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of bronchopulmonary dysplasia treatment market over the forecast period. Growing research and development activities by pharmaceutical companies to develop innovative treatment option for bronchopulmonary dysplasia would boost the market in near future.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4389

Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition can cause serious complications during infancy and might requires hospitalization and intensive medical care, during the first 2 years after birth. The signs and symptoms for BPS includes shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation. The disease can cause from other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, that affects the development of the lungs.

Bronchopulmonary Dysplasia Treatment Market: Key Players

Some of the players in global bronchopulmonary dysplasia treatment market include Airway Therapeutics LLC, Chiesi Farmaceutici SpA, Insmed Incorporated, MediPost Co., Ltd., Meridigen Biotech Co., Ltd, Syntrix Biosystems, Inc., Therabron Therapeutics, In,

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4389

Bronchopulmonary Dysplasia Treatment Market: Segmentation

The global bronchopulmonary dysplasia treatment market is classified on the basis of drug class, therapy type end user, and geography.

Based on drug type, the global bronchopulmonary dysplasia treatment market is segmented into the following:

Bronchodilators
Diuretics
Antibiotics
Steroids
Immunomodulators
Surfactant Homeostasis

Based on therapy type, the global bronchopulmonary dysplasia treatment market is segmented into the following:

Nitric Oxide Therapy
Protein replacement therapy
Stem Cell Therapy
Supplemental Oxygen

Based on end user, the global bronchopulmonary dysplasia treatment market is segmented into the following:

Hospitals
Nursing Homes
Critical Care Centers

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/4389

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain

https://www.fmiblog.com/2022/08/22/soft-tissue-repair-market-is-projected-to-reach-nearly-us-15500-million-by-2022-end-2/

https://www.fmiblog.com/2022/08/22/sleep-aid-devices-market-is-projected-to-surpass-us-133211-98-million-by-2032/

https://www.fmiblog.com/2022/08/22/animal-model-market-is-projected-to-be-valued-at-us-1-7-billion-in-2022-2/

https://www.fmiblog.com/2022/08/22/dermal-fillers-market-current-trends-and-future-growth-estimations-outlook-to-2031-3/

https://www.fmiblog.com/2022/08/22/pipette-tips-market-is-projected-to-surpass-usd-1-47-billion-by-2032-2/

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Pipette Tips Market is projected to surpass USD 1.47 Billion by 2032

[333 Pages Report] The pipette tips market is worth USD 680.40 million in 2022 and is expected to grow at an 8.0% CAGR from 2022 to 2032 to reach USD 1.47 billion by 2032.

Constant product innovation, rising demand for R&D, and an increasing number of healthcare settings, diagnostics, and liquid handling systems are key drivers driving pipette tips market growth as well as the pipette tips market opportunities.

Attributes	Details
Pipette Tips Market CAGR (2022-2032)	8.0%
Pipette Tips Market Size (2022)	USD 680.40 million
Pipette Tips Market Size (2032)	USD 1.47 billion

Furthermore, there has been an increase in the number of innovations in this product category, which is fuelling demand for pipette tips. Pipette tips, such as wide orifice tips, gel loading tips, standard, filtered, low-retention pipette tips, and so on, saw a significant increase in demand for pipette tips following the emergence of COVID-19 in 2020, as they were among the critical laboratory devices used to detect the virus’s presence.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15166

The filter tips product type segment of the pipette tips market in the United States is expected to grow at the fastest CAGR during the forecast period. The robotics segment had the largest pipette tips market share.

The demand for pipette tips increased dramatically as a result of the COVID-19 outbreak, as daily testing at diagnostic centres for infection detection increased influencing the pipette tips market adoption trends. However, many supply chain bottlenecks were encountered as demand for pipette tips outstripped supply.

Revenue from sales of pipette tips market increased significantly in the second half of 2020, particularly in the United States and Europe. Manufacturers of pipette tips are constructing a new plant for high-quality laboratory consumables made of functional high-tech polymers which will positively affect the pipette tips market key trends and opportunities as well as the pipette tips market future trends.

Eppendorf stated in its 2021 annual pipette tips market report that sales of pipette tips majorly its robotic pipetting systems have increased and have more than doubled since 2020. This suggests that demand for pipette tips notably robotic pipettes will rise as well along with the constructive effect on the pipette tips market future trends.

KEY TAKEAWAYS:

The standard product segment dominates the pipette tips market in product insight. It accounts for 32.5% of total revenue and is expected to grow at a healthy rate in the future.
In terms of technology insight, the non-robotic pipette tip segment is anticipated to have highest revenue in the pipette tips market share of 56.4% through 2032 and is expected to grow significantly during the forecast period.
In terms of application insight, the pharma and biotech segment dominates the pipette tips market, accounting for 32.3% of total revenue. The segment is expected to grow at the fastest CAGR during the forecast period, maintaining its leading position in the pipette tips market.
North America dominates the pipette tips market, accounting for 37.5% of the total revenue.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15166

COMPETITIVE LANDSCAPE:

New market research report on pipette tips will offer valuable insight into the market, with a focus on some of the major players such as Thermo Fisher Scientific, Sartorius AG, CORNING INC., Mettler Toledo, Tecan Trading AG, Hamilton Company, Eppendorf AG, and others.

Pipette tips market participants’ key strategic initiatives include new product development, collaborations, regional expansions, and mergers.

RECENT DEVELOPMENT:

Collaboration:

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. announced a 15-year strategic collaboration agreement in 2022 to enable dedicated large-scale manufacturing in the United States of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline, resulting in increased use of essential lab supplies such as pipette tips.

Expansion:

Thermo Fisher Scientific announced a $140 million investment to expand its laboratory plastics disposables production in order to meet global demand for pipette tips during COVID-19 testing, as well as for the development and manufacturing of therapies and vaccines.

Acquisition:

Sartorius has acquired Biological Industries Ltd., a manufacturer of cell culture and molecular biology research products.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15166

Key Segments

By Product:

Standard
Filtered
Low-retention
Others

By Technology:

Robotic
Non-robotic

By Applications:

Diagnostics and Healthcare
Pharma and Biotech
Academia and Education
Others

About FMI:

Dermal Fillers Market Current Trends And Future Growth Estimations Outlook To 2031

According to this new report titled “Dermal Fillers Market: Global Industry Analysis (2012-2016) and Opportunity Assessment” that tracks the performance of the global dermal fillers market for a period of 10 years, the United States is a highly mature market with wide scale adoption of dermal fillers.

The global dermal fillers market is traversing a path from the growth phase to maturity as companies are focussing on developing variants of products currently available in the global dermal fillers market.

This new report published by Future Market Insights discusses the high pricing competition and discounting practices between companies as well as physician practices that inflate margins and tend to hamper global adoption of the dermal filler procedure by patients.

Request Sample Report @

https://www.futuremarketinsights.com/reports/sample/rep-gb-5699

Multiple applications of dermal fillers and increasing number of aesthetic surgeons are the main factors responsible for fuelling the growth of the global dermal fillers market

Apart from functioning as an anti-aging factor, dermal fillers are also helpful in the areas of treatments such as acne scars, enhancement of the dorsal area of hand, and for HIV induced lipoatrophy of facial area.

Besides, the use of dermal fillers for the treatment of paralysed vocal cords is also under consideration for approval from the FDA.

The demand for application specific product modules is driving the growth of the global dermal fillers market.

Another important factor that is boosting the growth of the global dermal fillers market is a sudden increase in the number of plastic surgeons and their network.

This increasing network is boosting the demand for aesthetic procedures, which in turn is fuelling the development of the global market.

The FDA has also given its approval for the use of dermal fillers in the area of dentistry.

This is particularly beneficial for dentists as they come across many such cases that require facial changeover, which is easily possible with the help of dermal filler procedures.

The other drivers associated with dermal filler procedure include lesser procedure time, minimum risk of complexity, and requirement of minimum infrastructure.

Read Report Overview @ https://www.futuremarketinsights.com/reports/dermal-fillers-market

Increasing focus on development of new products and market expansion strategies by direct presence or through affiliates as a key development strategy by companies is expected to increase the demand for dermal fillers during the forecast period.

Favourable support from the government in terms of approval for new entities and new application areas as well as the commercialization of novel solutions are factors boosting collaborations and partnership agreements between manufacturers.

Various companies are also developing application specific dermal fillers and expanding their product range such as, fillers specific for lip augmentation, specific dermal fillers for the dorsal area of hand and fillers to increase volume.

All these factors are creating a robust development in the global market for dermal fillers.

Buy Full Dermal Fillers Market Research Report @ https://www.futuremarketinsights.com/checkout/5699

The application of dermal fillers in dentistry is expected to make an impact on the global market over the forecast period

With a Compound Annual Growth Rate of 3.4% during the period of assessment, the dentistry application segment is projected to grow significantly in terms of revenue in the years to come.

The key reason behind this growth is an increasing usage of the dermal filler procedure in the area of dentistry.

The aesthetic restoration segment dominated the dermal fillers market in terms of revenue in 2016 and this trend is projected to continue throughout the forecast period.

Reconstructive surgery is expected to be the second most lucrative application segment, given the high rate of growth of orthopaedic procedures across the globe.

Global Dermal Fillers Market: Overview

Our forecasts indicate that the global dermal fillers market is expected to grow from an estimated value of more than US$ 3,600 Mn in 2017 to just over US$ 4,960 Mn by the end of the forecast period in 2027.

This represents a CAGR of 3.2% in terms of revenue over the forecast period of 2017 to 2027. The global market for dermal fillers represents absolute $ opportunity of more than US$ 115 Mn in 2018 over 2017 and an incremental opportunity of more than US$ 1,300 Mn between 2017 and 2027.

About Future Market Insights (FMI)

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse latest Market Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Animal Model Market is projected to be valued at US$ 1.7 Billion in 2022

[170 Pages Report] According to a recently compiled study by Future Market Insights, the global animal model market will reflect an impressive CAGR through the forecast period, 2017 to 2026. Revenues from the global market for animal model are poised to surpass US$ 2,200 Mn by 2026-end.

Leveraging Animal Models offers Better Understanding of Different Diseases

Animals and human beings share a common biological as well as physiological structure. Animals possess shorter life cycle, however they have high genotype resemblance. It is simple and easy to control the animal environment as compared to the human beings.The animal models are increasingly being used in the biomedical research that helps to develop new treatment methods for various diseases. Leveraging animal models offers a better understanding of different diseases, along with the efficacy of drugs with regard to the diseases.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3141

Owing to these factors, demand for animal models has been witnessing a significant surge in the healthcare sector. Alternatives such as cell cultures, tissue cultures, and computer models are also available, however animal models are more preferred owing to the complexity of the living systems. This further makes animal models an effective choice for biomedical research.

Development of animal models, which are more predictive in being effective is an iterative process. However, progress is being made, with researchers applying new experimental approaches to elucidate the biology of specific diseases for the creating of new and efficient animal models.

During the development of new drugs dedicated to complex diseases, researchers are being well advised for testing drugs in multiple animal models as well as in mouse strains with different genetic backgrounds.

Researchers are also focusing on employing translational efficacy or pharmacodynamic biomarkers for linking efficacy observed in clinical results with pre-clinical analyses.

animal model market

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3141

Key Takeaways from FMI’s Report on Global Animal Model Market

North America is expected to remain the largest and fastest expanding market for animal model, with revenues estimated to surpass US$ 800 Mn by 2026-end. Between animal model markets in Asia-Pacific and Europe, the former will account for relatively larger revenue share, whereas the latter will expand at a comparatively higher CAGR through 2026. Although the market in South Korea will account for the lowest market revenue share, revenues are projected to expand at a relatively higher CAGR than those from the markets in Latin America and Middle East & Africa (MEA) through 2026.
On the basis of species, revenues from rats and mice are projected to account for over two-fifth share of the market by 2026-end. Revenues from use of rats in animal models will expand at the highest CAGR in the market through 2026. In addition, revenues from use of cats and monkeys in animal models will rise at a nearly equal CAGR through 2026. Dogs and pigs are expected to remain the least lucrative species used in animal models during the forecast period.
Contract research organizations (CROs) and biotechnology companies are anticipated to remain the fast expanding end-users of animal models. Revenues from these two end-users are collectively forecast to surpass US$ 850 Mn by 2026-end. In terms of revenues, academic & research institutions and pharmaceutical companies will continue to be dominant end-users in the global animal model market.
Basic and applied research application of animal model will continue to register the fastest expansion through 2026. However, drug discovery/development will remain the most lucrative application of animal model.
Key companies actively contributing to growth of the global animal model market include Transposagen Biopharmaceuticals, Inc., Envigo CRS SA, Crown Bioscience, Inc., Eurofins Scientific SE, Genoway SA, Taconic Biosciences, Inc., Trans Genic Inc, The Jackson Laboratory, Horizon Discovery Group plc, and Charles River Laboratories International, Inc.

Key Segments of Animal Model Industry ResearchAnimal Model Market by Species:

Rats
Mice
Guinea Pigs
Rabbits
Monkeys
Dogs
Pigs
Cats
Other Species

Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-3141

Animal Model Market by End User:

Academic & Research Institutions
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
Other End Users

Animal Model Market by Application:

Basic and Applied Research
Drug Discovery/Development

Animal Model Market by Region:

North America Animal Model Market
Latin America Animal Model Market
Europe Animal Model Market
East Asia Animal Model Market
South Asia & Pacific Animal Model Market
Middle East & Africa (MEA) Animal Model Market

About FMI:

Soft Tissue Repair Market is projected to reach nearly US$ 15,500 Million by 2022-end.

A new report by Future Market Insights (FMI) anticipates the global soft tissue repair market to exhibit a steady 5.5% CAGR throughout the forecast period (2017-2022). The global market for soft tissue repair is expected to account for over US$ 15,000 Mn revenues by 2022-end.

Advancements in Products such as Bioabsorbable Soft Tissue Screws to Propel Growth of the Market

A number of technological advancements and innovations have been observed in orthopedic connective tissue repair procedures. Novel advances, for instance – the innovative surgical techniques, are being made in the procedures associated with anterior cruciate ligament (ACL) reconstruction, in a bid to make the process more effective. Global leaders, including Zimmer Biomet and NORAKER, have been developing new bioabsorbable soft tissue screws over the past few years. Leading market players have also been focusing on development of the mesh with biological products, which would act as a replacement for human allograft. An example of this is development of EZ Derm by MoInlycke Health Care, utilized as dressing for wounds using wires and pins independently, or together, with various other internal fixation devices. These devices are utilized for surgeries pertaining to hip replacement and spine.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4931

People across the globe are becoming aware of development, promotion, and commercialization of the advanced platelet-rich plasma devices, used for musculoskeletal disorders. In addition, there is a surge in awareness about skeletally immature patients to have a high risk of tear in the connective tissue and ligaments. These factors might positively impact global demand for soft tissue repair in the near future.

Sports-related Injuries- A Major Factor Driving the Market Growth

A major factor affecting demand for soft tissue repair is injuries related to sports. Athletes usually suffer from ACL tear during the game, or while performing other physical activities. Moreover, increasing aging population is also expected to play an imperative role in growth of the market. With aging, substantial changes are observed in skeletal and neuromuscular systems, which in turn leads towards ACL tear, weak ligaments and arthritis. Prevalence of obesity in geriatric population is directly increasing risk of degenerative bone diseases, such as osteoporosis and osteoarthritis. The aforementioned factors are further expected to increase demand for soft tissue repair procedures.

In contrast, high prices associated with soft tissue repair procedures, lack of awareness in population across underdeveloped and remote regions, and unfavorable reimbursement policies are factors which will impede demand for soft tissue repair procedures in the near future.

APEJ to Witness a Significant Expansion in the Market

The soft tissue repair market in Asia-Pacific excluding Japan (APEJ) is expected to witness a significant growth, with revenues poised to surpass US$ 3,000 Mn by 2022-end. Growth of the market in APEJ can be primarily attributed to increasing purchasing power of population, and rising prevalence of musculoskeletal disorders in countries such as India and China. In addition, North America is expected to remain the most attractive market for soft tissue repair, owing to the hike in healthcare expenditure in this region.

Based on product, sales of laparoscopic instruments, and synthetic mesh are expected to collectively account for over one-third revenue share of the market during the forecast period. Sales of synthetic mesh and laparoscopic instruments will register similar CAGRs through 2022.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4931

Orthopedic Application of Soft Tissue repair to Account for Largest Revenue Share

Orthopedic application of soft tissue repair are expected to account for the largest revenue share of the market during 2017 to 2022, followed by skin repair application. In addition, revenues from orthopedic and skin repair application of soft tissue repair are expected to collectively account for over US$ 7,000 Mn by 2022-end.

Accounting for around two-third revenue share of the market, hospitals are expected to remain the most lucrative end-users in the global market for soft tissue repair. Revenues from hospitals in the market are expected to reach approximately US$ 10,000 Mn by 2022-end.

Key players profiled by the FMI’s report, who are actively operating in the global soft tissue repair market, include

Wright Medical Group N.V.
Integra LifeScience Corporation
Medtronic Plc.
CONMED Corporation
C. R. Bard Inc.
Braun Melsungen AG
Smith & Nephew
DePuy Synthes
Stryker Corporation
Zimmer Biomet Holdings Inc.
Arthrex Inc.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-4931

Market TaxonomyIn one of its chapters, the report provides an in-depth analysis of the market segmentation, which is based on product, application, end-user, and region. The report offers insights on every market segment and its sub-segments in terms of absolute $ opportunity, Y-o-Y growth, market attractive index, market size, and BPS analysis.

Product

Allograft
Xenograft
Synthetic Mesh
Interference Screws
Suture Anchors
Laparoscopic Instruments
Other Fixation Devices

End User

Hospitals
Clinics
ASCs

Application

Breast Reconstruction Repair
Dental
Dural Repair
Hernia Repair
Orthopedic
Skin Repair
Vaginal Sling Procedures
Others

About FMI:

Nerve Repair Market is expected to be valued at nearly US$ 430 Million by 2027

The global nerve repair market is expected to be worth more than US$ 145 million in 2017 and nearly US$ 430 million by 2027, growing at a CAGR of 11.3 percent over the forecast period.

Future Market Insights (FMI) in its latest report titled “Nerve Repair Market: Global Industry Analysis and Opportunity Assessment 2017-2027” identifies that ageing is one of the major factors that increases possibilities of nerve damage. Occurrence of nerve damage is medically-proven to be higher amongst aged people, hence, the rising geriatric population across the globe is fueling the demand for nerve repair products. As per the FMI report, global nerve repair market will ride at an impressive CAGR of 11.3% in terms of revenue during the forecast period (2016-2027). Moreover, increasing government initiatives to spread awareness about new nerve repair treatments and availability of advanced treatment therapies is expected to boost the growth of global nerve repair market over the next couple of years.

A damaged nerve can result in severe sensory and motor complications, which may cause severe pain as well as malfunctioning of the appendages. In these conditions, repairing of damaged nerves becomes quite imperative. Fortunately, a range of medical products is available in the market for treating damaged nerves. Nerve protectors, nerve connectors, nerve wraps and nerve grafts are amongst some of the popular products used for nerve repairing. As these products become medically more effective, their demand continues to grow.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2680

Nerve Repair Treatment: Market Opportunities

Currently, most of the leading medical companies that manufacture nerve repair products are mainly concentrated in developed regions such as Europe and North America. Many of the developing countries including Mexico, India, Indonesia and few other countries from the Middle East are yet to witness widespread penetration of the nerve repair biomaterial products. The scope of promoting the products in such emerging markets would definitely bring in lucrative business opportunities for medical companies. Therefore, tapping emerging markets is likely to create opportunities for growth in term of sales of nerve repair products. Some of the leading medical companies are focusing on aspects such as training of physicians and marketing of their products in these developing regions. Axogen, Inc., Baxter International Inc., Stryker Corporation, Integra Lifesciences, Holdings Corp, Neurotex, Ltd. and Polyganics B.V. are some leading medical companies partaking in the growth of global nerve repairing market.

North America Nerve Repair Market to Maintain its Speedy Growth

In 2016, the nerve repair market in North America captured more than 40% share in terms of revenue. The expanding base of geriatric population and rising demand for advanced medical technology in the U.S. continues to create new market opportunities for manufacturers of nerve repair products in the region. Meanwhile, demand for nerve repair products in Japan has been overwhelmingly high in recent years and similar trends are expected to continue throughout the forecast period. In addition, nerve repair market in Japan is expected to expand at an impressive CAGR of 10.8% over the forecast period owing to increasing healthcare awareness and demand for advanced medical technology.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2680

Additional Highlights of the Report Include:

Nerve graft is the most popular nerve repairing product type and is estimated to account for around 40.3% revenue share of the global market by 2017-end.
Repairing of epineural nerves is expected to remain the highest amongst all the types of nerve repair. Towards the end of the assessment period, revenue from epineural nerve repairing is estimated to reach US$ 290.3 Mn.
Hospitals will remain as the largest end user of nerve repair products and are projected to account for over 61% value share of the market by end of 2027.

Market Taxonomy

Nerve Repair Type

Epineural Nerve Repair
Perineural Nerve Repair
Fascicular Nerve Repair

Product Type

Nerve Wraps
Nerve Protectors
Nerve Connectors
Nerve Grafts

End User

Hospitals
Ambulatory Surgical Centres
Speciality Clinics

About FMI:

Paediatric Vaccine Market is projected to reach a value of US$ 13.49 Billion by 2026

According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016.

Paediatric vaccine market is a billion dollar market accounting for a substantial proportion of healthcare expenditure in the recent times. The paediatric vaccine market is segmented according to indication, technology and vaccine type. According to the indication, the paediatric vaccine market is sub segmented into pneumococcal, DTP, rotavirus, influenza, meningococcal, hepatitis B, Hib, MMR and polio. According to technology the market is further segmented into live or attenuated, inactivated or killed, toxoid, conjugate, subunit and recombinant vaccines. By vaccine type, the global paediatric vaccine market is segmented into monovalent and multivalent vaccines.

A slew of routine immunisation initiatives rolled out by the government and private agencies has broadened the market for the paediatric vaccines. A new wave of funds pumped into the market by different government and private players to cork the rise of the child deaths across the globe has also opened a new window of opportunity for the paediatric vaccine market. As per the report of WHO (World Health Organization), the global spending on immunisation soared from US$21.4 to US$26.9 per infant in 2014. The massive economic boom in some regions of the world is expediting the growth of the paediatric vaccine market.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1317

Segmentation analysis

By indication, pneumococcal segment accounted for higher revenue share in global paediatric vaccines as compared to other product segments. The pneumococcal segment is expected to reach a value of US$ 31.58 Bn by 2026, reflecting a CAGR of 14.4% over the forecast period. The growth of pneumococcal segment is attributed to the increasing incidence of infectious diseases.

In terms of revenue, Hib vaccine segment is the second most growing segment and is expected to reach a value of US$ 13.49 Bn by 2026, growing at a CAGR of 13.4%. Hepatitis B and meningococcal segment are expected to show double-digit CAGR growth in the forecast period contributing to the growth of global paediatric vaccine market.

By technology, conjugate segment accounted for highest revenue share in global paediatric vaccine market as compared to live or attenuated segment. The conjugate segment is expected to reach a value of US$ 32.09 Bn by 2026, reflecting a CAGR of 14.8% over the forecast period. This is expected to be closely followed by the growth of pneumococcal and meningococcal vaccines in this segment

By end user, institutional health centres account for higher demand for paediatric vaccine as compared to other end user segments such as hospital pharmacies and retail pharmacies. The strong growth in institutional health centres can be attributed to increasing government interventions in immunisation programs in order to improve vaccine coverage. Institutional health centres are expected to register highest CAGR of 13.8% over the forecast period.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1317

Regional analysis

By region, North America is dominating the global paediatric vaccine market due to improved healthcare infrastructure in this region. The North America paediatric vaccine market is expected to be valued at US$ 20.15 Bn by 2026 growing at a CAGR for 11.0%. In addition to North America, demand for paediatric vaccines has been significantly growing in Western Europe and APEJ. APEJ is expected to grow at a CAGR for 14.9% over the forecast period and is expected to dominate the market by 2026 by generating revenue of US$ 22.69 Bn and revenues in Western Europe are anticipated to grow by 11.2%. Middle East and Africa is expected to grow at a CAGR of 12.6% and this growth is anticipated by growth government intervention for immunisation by carrying out national level immunisation campaigns and also disease specific immunisation campaigns.

Key players in the global paediatric vaccine market include

Indian Immunologicals,

GlaaxoSmithKline Plc.,

Pfizer Inc.,

Sanofi, Merck & Co. Inc.,

Panacea Biotec,

Zydus Cadila,

Emergent BioSolutions Inc.,

Serum Institute of India Pvt. Ltd.,

Bharat Biotech.

The growth of paediatric vaccine market is attributed to the development in the research by key players in the field, for instance, in February 2016, GSK submitted US regulatory submission for expanding the indication of FLuLaval Quadrivalent, influenza vaccine, for infants more than 6 months. These developments will boost the growth of the global paediatric vaccine market.

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1317

Market Segmentation

Region

North America
Latin America
Western Europe
Eastern Europe
APEJ
MEA
Japan

Technology

Live or Attenuated Vaccine
Inactivated or Killed Vaccine
Toxoid Vaccine
Conjugate Vaccine
Subunit Vaccine
Recombinant Vector Vaccine

Indication

Pneumococcal Conjugate Vaccine
DTP Vaccine
Influenza
Meningococcal Vaccine
Polio Vaccine
Rotavirus Vaccine
MMR Vaccine
Varicella Virus Vaccine

End User

Hospital Pharmacies
Retail Pharmacies
Institutional Health Centres

Vaccine Type

Monovalent Vaccines
Multivalent Vaccines

About FMI:

Oncology Information Systems Market is projected to grow to US$ 5.4 Billion by 2032

[333 Pages Report] The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information system market is expected to grow from USD 2.59 billion in 2022 to USD 5.48 billion by 2032.

The increasing incidence and prevalence of cancer, as well as the growing need to reduce the cost of cancer care, are driving the oncology information system marketgrowth, as are the potential benefits offered by oncology information systems in cancer treatment, management, and planning.

Attributes	Details
Oncology Information Systems Market CAGR (2022-2032)	7.8%
Oncology Information Systems Market Size (2022)	USD 2.59 Billion
Oncology Information Systems Market Size (2032)	USD 5.4 Billion

Get a Sample Copy of the Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15150

The oncology information system market includes software and services used for comprehensive information and image management, which aids in the management and optimization of cancer patient profiles and treatment.

Leading oncology information system marketplayers’ sales and operating incomes have decreased as a result of COVID-19. Inventory was reduced as a result of tight production controls.

The rising incidence of cancer cases is one of the major factors driving the oncology information system marketgrowth. There are a few other factors driving the oncology information system market key trends and opportunities, such as the growing need to reduce oncology care costs and the growing adoption of oncology information system along with electronic health records (EHR) and other oncology information systems.

A major impediment to implementing OIS solutions in hospitals is a lack of qualified resources influencing the oncology information system market future trends along with oncology information system market opportunities. Currently, the demand for healthcare IT professionals outnumbers supply in both developing and developed oncology information system market, including the United States and Europe.

Asia Pacific accounted for 17.8% of the oncology information system market. The Asia Pacific oncology information system market is expanding due to several factors, including rising cancer prevalence and increased investment in the implementation of IT solutions in healthcare settings which h influences the oncology information system market adoption trends.

KEY TAKEAWAYS:

The oncology information system market has been divided into two segments: solutions and professional services. The solutions segment accounted for the majority of revenue i.e. 73.4%.
The solutions segment is further subdivided into patient information systems and treatment planning systems, with the latter accounting for the lion’s oncology information system marketshare.
Medical oncology accounted for the largest oncology information system marketshare of global revenue, accounting for 61.4% of total revenue.
In 2021, the North America regional oncology information system market had the highest oncology information system marketshare’s revenue of 38.5%.
The software segment accounted for 83.6% of the product and service oncology information system market.
Radiation oncology accounted for 53.8% of the oncology information system market.
Asia Pacific accounted for 17.8% of the oncology information system market.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15150

COMPETITIVE LANDSCAPE:

Key oncology information system marketcompanies are primarily focused on incorporating technological innovation with the introduction of web-based oncology solutions and AI-based oncology information system solutions with the goal of improving the treatment regime, which is expected to positively impact oncology information system marketgrowth in the near future.

Prominent Players :

Elekta AB
Accuray Inc.
Varian Medical Systems
RaySearch Laboratories
Cerner Corp.
BrainLab
Philips Healthcare
Prowess, Inc.
DOSIsoft S.A.
ViewRay Inc.
MIM Software
Flatiron

RECENT DEVELOPMENT:

Varian Medical Systems, Inc. announced a USD 10.0 million investment and a strategic collaboration agreement with COTA, Inc., a curator of clinical data in the oncology sector, in 2020.
Siemens Healthineers (Germany) completed the acquisition of Varian Medical System in August 2021. (UK). The goal of this acquisition was to create a one-of-a-kind, highly integrated portfolio of oncology information system workflow.
Koninklijke Philips N.V. (The Netherlands) and Elekta (Sweden) will collaborate in June 2021 to develop advanced, comprehensive, and personalised cancer care through precision oncology information solutions.
McKesson Corporation (US) has launched Ontada, an oncology technology and insights business dedicated to advancing cancer research and care, in December 2020.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/15150

Key Segments

By Product:

Solutions
- Patient Information Systems
- Treatment Planning Systems
Professional Services

By Application:

Medical Oncology
Radiation Oncology
Surgical Oncology

About FMI:

Thiamine Market is predicted to grow at a healthy CAGR of 13.9% from 2022 to 2032

[342 Pages Report] The thiamine market is expected to see a significant CAGR of 13.9%, and is projected to increase from US$ 170.9 million in 2021 to US$ 715.32 million by 2032.

Attributes	Details
Thiamine Market CAGR (2022-2032)	13.9%
Thiamine Market Size (2021)	US$ 170.9 million
Thiamine Market Size (2032)	US$ 715.32 million

Thiamine’s expanding use in mental health is driving up the market size, as its uses go beyond only physical health. Additionally, the market leaders for thiamine, like Jiangsu Jubang Pharmaceutical Co. Ltd, work hard to preserve their leadership positions by bringing in the biggest percentage of revenue and snatching up the largest portion of the market.The product’s expanding function in energy metabolism, as well as the growth and development of healthy cells, is what largely drives the thiamine market. The growing demand for thiamine is mostly due to increased public awareness of the human body’s thiamine deficiency.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15349

Sales of thiamine are expanding, as it is used by both humans and animals. Animals are given the chemical to protect their livers and kidneys against lead-induced lipid peroxidation. It is essential for both the development and growth of healthy cells, as well as for human energy metabolism.

The increased frequency of illnesses and the lack of knowledge and awareness surrounding thiamine deficiency may be limiting factors for the growth of the thiamine market. Furthermore, this shortage can lead to a number of other serious health issues.

Due to the country’s rising healthcare spending, aging population, improved medical facilities, changing pharmacy distribution networks, and cutting-edge technologies, the United States is one of the main consumers of protein components.

Key Takeaways of the Thiamine Market

The thiamine market is expected to have a CAGR of 9% during the forecast period.
The thiamine market is anticipated to have a valuation of US$ 715.32 million by 2032.
The thiamine market had a valuation of US$ 170.9 million in 2021.
The thiamine market is segmented based on surgical application, wherein the dietary supplementary segment had a CAGR of 1% in 2021.
The pharmaceutical segment holds the second leading position as a result of the usage of thiamine in treatments for a number of disorders.
The Asia Pacific dominated thiamine market, with a CAGR of 0% in 2021.
The North America thiamine market is expected to expand rapidly, with a prodigious share during the forecast period.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15349

Competitive landscape: Fresh Companies Are Meeting The Product Demand

Due to the increasing customer demand for the products and the dwindling supply of manufacturers, there are many opportunities for the existing firms to gain a strategic and competitive advantage. With the assistance of experienced and productive R&D, new businesses can create goods that are ready for the market.

In order to gain a competitive edge and ensure consumer satisfaction, the top players in the thiamine market have taken a number of strategic actions, including setting up various research programs, lowering prices, and carrying out profit-making and expansion initiatives.

Recent Developments: Innovations and Product launches

The US Food & Drug Administration (USFDA) has given final permission for Aurobindo Pharma Limited to produce and sell Thiamine HCl Injection 200 mg/ 2 mL Multi-Dose Vials.
February 18, 2021 – Through its US subsidiary, Hikma Pharmaceuticals USA Inc. The multinational pharmaceutical business Hikma Pharmaceuticals PLC (Hikma) has introduced Thiamine Hydrochloride Injection, USP, 200mg/2mL, in the US.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15349

Key players

DSM
Chemizo Enterprise
Xinfa Pharmaceutical Co., Ltd.
Jiangxi Tianxin Pharmaceutical Co., Ltd.
Nutricost
McCartan’s Pharmacy
Jiangsu Jubang Pharmaceutical Co., Ltd.
HPC

Key segments

By Application:

Food & Beverages
Animal Feed
Pharmaceuticals
Dietary Supplements

By Region:

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

About FMI:

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Microbial Therapeutic Products Market reach a valuation of US$ 30.55 Billion by the end of 2030

Future Market Insights’ (FMI) global microbial therapeutic products report provides an exhaustive yet unbiased analysis of future growth projections, taking into account the aforementioned developments to provide a bird’s eye view of the landscape. According to the study, demand for microbial therapeutic products is likely to grow at a steady clip, driven chiefly by growing incidence of antimicrobial resistance.

Over the years, the burden of antimicrobial resistance (AMR) has been escalating tremendously, besides prevalence of chronic conditions. The World Health Organization observes high resistance rates have been observed against antimicrobials used for treating urinary tract infections and certain types of diarrhea. For example, the rate of resistance to ciprofloxacin ranged anywhere between 8.4% and 93% across 33 countries. It is apprehended that this burden is compounding further due to the COVID-19 pandemic. Hence, efforts are underway to accelerate research for discovering breakthroughs in microbial therapeutics.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-12891

Key Takeaways

By product, anti-cancer agents to capture nearly 30% revenue by 2020-end, owing to prolific research breakthroughs
By route of administration, injection pens to account for 2 out of 5 sales, attributed to patient hygiene concerns
By source, bacteria based microbial therapeutic products to remain preferred
Oncology to remain primary microbial therapeutic products application area, expanding at Y-o-Y rate exceeding 5% through 2020
Hospitals emerge as the primary microbial therapeutic end-users, attributed to availability of adequate infrastructure
North America to remain the market hegemon, East Asia to be fastest growing market

“Prominent manufacturers are seeking regulatory approvals to accelerate research and development operations for developing effective drug solutions to address the compounding antimicrobial resistance problems,” remarks the FMI analyst.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-12891

COVID-19 Impact Analysis

The COVID-19 pandemic has adversely impact global economic outlook, with a prolonged recession on the cards across numerous industries. However, the microbial therapeutic products market has only stood to benefit from the pandemic crisis, as the global healthcare community accelerates efforts to find a potential cure for this deadly virus.

With inoculation procedures already being initiated across the U.K., it is only a matter of time before the anti-COVID-19 vaccine is available on a global scale. Despite this availability, healthcare providers will have a long road ahead with respect to discovering an orally administered drug formulation.

Therefore, governments are lending unconditional support to the global healthcare fraternity in terms of policy relaxation and disbursement of financial grants to aid in the research and development process, catapulting growth prospects.

Competitive Landscape

Prominent players operating in the global microbial therapeutic products market are emphasizing on acquiring regulatory approvals, forging partnerships and collaborations with competent authorities and biosimilars develop to capture substantial revenue shares across key regions.

Some reputed players operating within the global microbial therapeutic products landscape include Dr. Reddy’s Laboratories, Pfizer Inc., Sanofi SA, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Abbott Laboratories and Amgen Inc. to name a few.

In November 2020, Dr. Reddy’s Laboratories announced a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire its anti-allergy brands Momat Rino, Momat Rino Advance and Momat A to market them across Russia, Kazakhstan and Uzbekistan respectively.

In December 2020, Novo Nordisk announced the acquisition of Emisphere Technologies to exercise ownership of its Eligen SNAC oral delivery technology. The acquisition shall accelerate its GLP-1 receptor agonist seaglutide’s production on a larger scale.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-12891

More Valuable Insights on FMI’s Microbial Therapeutic Products Market

Future Market Insights, in its new report, offers an unbiased analysis of the global microbial therapeutic products market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the microbial therapeutic products market on the basis of product (growth factors, anti-cancer agents, immunosuppressants, enzymes & others), route of administration (single use pre-filled injection/injection pen, multi-use injectors & others), source (bacteria & fungi), application (metabolic disorders, haematological disorders, oncology, immunological disorders, infectious diseases, allergic diseases & others) and end-user (hospitals, pharmaceuticals & biopharmaceutical companies and research & academic institutions) across seven prominent regions.

About FMI:

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs